Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy

被引:16
|
作者
Nagalla, Srikanth [1 ]
Sarode, Ravi [1 ,2 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Div Transfus Med & Hemostasis, Dallas, TX 75390 USA
关键词
Antiplatelet therapy; Aspirin; P2Y12; inhibitors; Platelet transfusion; ACETYLSALICYLIC-ACID; ASPIRIN; CLOPIDOGREL; INHIBITION; PHARMACOLOGY; HEMORRHAGE; TICAGRELOR; REACTIVITY; SECONDARY; STROKE;
D O I
10.1016/j.tmrv.2019.01.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiplatelet therapy is extensively used in the primary and secondary prophylaxis of arterial thrombotic disorders. Aspirin, the most commonly used antiplatelet agent, is a cyclooxygenase-1 inhibitor and considered a mild to moderate inhibitor of platelet function. Therefore, often a second antiplatelet agent is necessary in certain clinical conditions requiring greater inhibition of platelet function. An adenosine diphosphate (ADP) receptor, P2Y12, is an important target for this purpose; several agents inhibit this receptor providing potent antiplatelet effect. One of the side effects of these agents is bleeding, which in some patients may require reversal of antiplatelet effect. Similarly, patients undergoing emergent surgeries may benefit from reversal of antiplatelet effect to avoid excessive surgical bleeding. This article reviews current literature on this topic. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 50 条
  • [31] Quality assessment of platelet rich plasma during anti-platelet therapy
    Smith, Chad W.
    Binford, Robert S.
    Holt, David W.
    Webb, David P.
    [J]. PERFUSION-UK, 2007, 22 (01): : 41 - 50
  • [32] Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy
    Adam S. Fisch
    Christina G. Perry
    Sarah H. Stephens
    Richard B. Horenstein
    Alan R. Shuldiner
    [J]. Current Cardiology Reports, 2013, 15
  • [33] ANTI-PLATELET AGENTS .4. SELECTION OF ANTI-PLATELET AGENTS
    LEVYTOLEDANO, S
    [J]. REVUE DE MEDECINE, 1979, 20 (18): : 913 - 919
  • [34] Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy
    Wolska, Nina
    Rozalski, Marcin
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (21)
  • [35] DERMATOMYOSITIS ASSOCIATED WITH PLATELET THROMBI FORMATION AND RESPONSIVE TO ANTI-PLATELET THERAPY
    LITTLEJOHN, GO
    DECK, JHN
    KELTON, JG
    REYNOLDS, WJ
    [J]. JOURNAL OF RHEUMATOLOGY, 1983, 10 (01) : 136 - 139
  • [36] Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy
    Fisch, Adam S.
    Perry, Christina G.
    Stephens, Sarah H.
    Horenstein, Richard B.
    Shuldiner, Alan R.
    [J]. CURRENT CARDIOLOGY REPORTS, 2013, 15 (07)
  • [37] INFERIOR VENA-CAVA REPLACEMENT - THE ROLE OF ANTI-PLATELET THERAPY
    LOVAAS, ME
    GLOVICZKI, P
    DEWANJEE, MK
    HOLLIER, LH
    KAYE, MP
    [J]. JOURNAL OF SURGICAL RESEARCH, 1983, 35 (03) : 234 - 242
  • [38] Chronic hepatitis B: role of anti-platelet therapy in inflammation control
    Roberto Aiolfi
    Giovanni Sitia
    [J]. Cellular & Molecular Immunology, 2015, 12 : 264 - 268
  • [39] Successful administration of unilateral spinal anaesthesia in a patient receiving dual anti-platelet therapy under platelet transfusion cover
    Arya, Abhishek
    Turki, Sonali
    Chauhan, Rajeev
    Kanth, Gorla
    [J]. INDIAN JOURNAL OF ANAESTHESIA, 2022, 66 (04) : 300 - 302
  • [40] Anti-platelet therapy and managing ulcer risk
    Chan, Francis K. L.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (02) : 195 - 199